Using Breakthrough Stem Cell Technology


Posted by iCELL News, on 06th March 2012, in Stem Cell Research.

Highlighted in Goldman Research Report with Near-Term Price of $0.50 Per Share 03/06 10:22 AM

SILVER SPRING, Md.–(BUSINESS WIRE)– Nuvilex, Inc. (NVLX:$0.062,0$-0.007,0-10.14%) , an emerging biotechnology provider of cell and gene therapy solutions, today pointed out the potential for substantial partnership and licensing opportunities using the company’s cell encapsulation technology for applications in stem cell research and medicine. Migration of implanted cells away from the target site and host rejection have been recognized as fundamental challenges faced by the stem cell community regarding their use in therapy, which the company’s technology overcomes.
The technology being acquired from associate SG Austria is used to place live stem cells into strong, flexible and permeable capsules. These capsules can then be implanted into animals or humans for specific therapies. Stem cells can then exist at the desired location inside the capsules, prevented from migrating and protected from the immune system that aims to eliminate such foreign cells from the body.
Stem cell therapy is being used by clinicians throughout the world for treating such diverse diseases as spinal cord injury, amyotrophic lateral sclerosis, burns, glioma, multiple myeloma, arthritis, heart disease, stroke, Stargardt’s Macular Dystrophy, and age-related macular degeneration, among others, most of which can be found at ClinicalTrials.gov.
Historically, researchers have faced numerous difficulties in succeeding with certain stem cell treatments, because of the problems associated with keeping stem cells alive for significant periods of time, stopping rejection and destruction by the recipient’s immune system, and keeping stem cells from migrating away from the desired sites. Cells encapsulated in SG Austria’s porous beads have been shown to remain alive for long periods of time in humans, surviving intact for at least two years. Once encapsulated, cells are protected from the body’s immune system. Furthermore, encapsulated cells remain within the beads and are unable to migrate to other sites in the body.
In the February 29, 2012 research report, Goldman Small Cap Research stated, “The Cell-in-a-Box® approach could significantly advance the implementation and utilization of stem cells for a host of debilitating diseases and conditions, making it a uniquely valuable commodity. We believe that by partnering with leading players in the field, Nuvilex (NVLX:$0.062,0$-0.007,0-10.14%) could find that companies with deep pockets would be happy to collaborate or license the delivery system and engage in further research which could result in meaningful development and licensing revenue.”
Dr. Robert Ryan, Chief Executive Officer of Nuvilex (NVLX:$0.062,0$-0.007,0-10.14%) , discussed the value for licensing the company’s stem cell therapy, adding, “By overcoming traditional barriers to effective stem cell therapy, namely viability, migration, and host rejection, we believe these new advances in medical science utilizing stem cells and encapsulation will enable us to take quantum leaps forward now and in the future. As a result of challenges SG Austria has overcome, new advances will be surprisingly close at hand and are part of the driving force behind our desire to work with a number of companies in this endeavor. Our primary goal has been and remains to use our technology to bring life changing treatments to patients on an expedited basis.”
About Nuvilex (NVLX:$0.062,0$-0.007,0-10.14%)
Nuvilex, Inc. (NVLX:$0.062,0$-0.007,0-10.14%) is an emerging international biotechnology provider of clinically useful therapeutic live encapsulated cells and services for encapsulating live cells for the research and medical communities. Through our effort, all aspects of our corporate activities alone, and especially in concert with SG Austria, are rapidly moving toward completion, including closing our agreement. One of our planned offerings will include cancer treatments using the company’s industry-leading live-cell encapsulation technology.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex (NVLX:$0.062,0$-0.007,0-10.14%) is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Source: Nuvilex, Inc. (NVLX:$0.062,0$-0.007,0-10.14%)